Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiayu Huang

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 30, 2013
Synaptic protein α1-takusan mitigates amyloid-β-induced synaptic loss via interaction with tau and postsynaptic density-95 at postsynaptic sitesNobuki Nakanishi, Scott D Ryan, Xiaofei Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 8, 2026
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in ChinaShun Lu, Jian Fang, Yan Yu, et al.
Nature Communications|April 18, 2019
Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patientsXu-Chao Zhang, Jun Wang, Guo-Guang Shao, et al.
Stem Cell Reports|August 30, 2016
Quantitative Analysis of Human Pluripotency and Neural Specification by In-Depth (Phospho)Proteomic ProfilingIlyas Singec, Andrew M Crain, Junjie Hou, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Nature Medicine|May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trialCaicun Zhou, Xiaorong Dong, Gongyan Chen, et al.
Cell Reports|July 9, 2014
S-nitrosylation-mediated redox transcriptional switch modulates neurogenesis and neuronal cell deathShu-Ichi Okamoto, Tomohiro Nakamura, Piotr Cieplak, et al.
Plos Pathogens|January 15, 2016
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortElise Landais, Xiayu Huang, Colin Havenar-Daughton, et al.
Nature Communications|November 15, 2017
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autismShichun Tu, Mohd Waseem Akhtar, Rosa Maria Escorihuela, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker ResultsPeter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 30, 2013
Synaptic protein α1-takusan mitigates amyloid-β-induced synaptic loss via interaction with tau and postsynaptic density-95 at postsynaptic sitesNobuki Nakanishi, Scott D Ryan, Xiaofei Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 8, 2026
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in ChinaShun Lu, Jian Fang, Yan Yu, et al.
Nature Communications|April 18, 2019
Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patientsXu-Chao Zhang, Jun Wang, Guo-Guang Shao, et al.
Stem Cell Reports|August 30, 2016
Quantitative Analysis of Human Pluripotency and Neural Specification by In-Depth (Phospho)Proteomic ProfilingIlyas Singec, Andrew M Crain, Junjie Hou, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Nature Medicine|May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trialCaicun Zhou, Xiaorong Dong, Gongyan Chen, et al.
Cell Reports|July 9, 2014
S-nitrosylation-mediated redox transcriptional switch modulates neurogenesis and neuronal cell deathShu-Ichi Okamoto, Tomohiro Nakamura, Piotr Cieplak, et al.
Plos Pathogens|January 15, 2016
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortElise Landais, Xiayu Huang, Colin Havenar-Daughton, et al.
Nature Communications|November 15, 2017
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autismShichun Tu, Mohd Waseem Akhtar, Rosa Maria Escorihuela, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker ResultsPeter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
Pageof 2